Sao Tome and Principe
Tuberculosis profile
Population  2013 <1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.018 (<0.01–0.038) 9.3 (4.6–20)
Mortality (HIV+TB only) <0.01 (<0.01–0.015) 4.7 (2.4–7.6)
Prevalence  (includes HIV+TB) 0.22 (0.11–0.36) 114 (59–187)
Incidence  (includes HIV+TB) 0.18 (0.16–0.2) 91 (81–103)
Incidence (HIV+TB only) 0.036 (0.032–0.041) 19 (17–21)
Case detection, all forms (%) 84 (74–94)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.9 (0.1–5.3) 88 (47–100)
MDR-TB cases among notified pulmonary
TB cases
3 (0–7) 15 (8–17)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 78   2
Pulmonary, clinically diagnosed 52   0
Extrapulmonary 15   0
       
Total new and relapse 147    
Previously treated, excluding relapses 15    
Total cases notified 162    
Among 147 new and relapse cases:
18 (12%) cases aged under 15 years; male:female ratio: 1.2
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 (1%) 2 (12%) 3
Laboratory-confirmed RR-/MDR-TB cases     3
Patients started on MDR-TB treatment     3
TB/HIV 2013 Number (%)
TB patients with known HIV status 147 (91)
HIV-positive TB patients 30 (20)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 30 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 30 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 70
Previously treated cases, excluding relapse, registered in 2012 42
HIV-positive TB cases, all types, registered in 2012 61
RR-/MDR-TB cases started on second-line treatment in 2011 100
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 4.1
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions) 2
% Funded domestically <1%
% Funded internationally 18%
% Unfunded 81%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-29 Data: www.who.int/tb/data